ClinicalTrials.Veeva

Menu

Rectal Surgery Evaluation Trial (RESET)

I

Institut du Cancer de Montpellier - Val d'Aurelle

Status

Completed

Conditions

Rectal Cancer

Treatments

Procedure: TME with LAR

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT03574493
PROICM 2018-03 ORE

Details and patient eligibility

About

Total mesorectal excision (TME) is the standard of care for rectal cancer, which can be combined with low anterior resection (LAR) in patients with mid-to-low rectal cancer. The narrow pelvic space and difficulties in obtaining adequate exposure make surgeries technically challenging. Four techniques are used to perform the surgery: open laparotomy, laparoscopy, robot-assisted surgery, and transanal surgery. Comparative data for these techniques is required to provide clinical data on the surgical management of rectal cancers by surgery.

Full description

The Rectal Surgery Evaluation Trial will be a prospective, observational, case-matched, four-cohort, multicenter trial designed to study TME with LAR using open laparotomy, laparoscopy, robot-assisted surgery, or transanal surgery in high-surgical-risk patients with mid-to-low, non-metastatic rectal cancer. All surgeries will be performed by surgeons experienced in a technique. Oncologic, morbidity and functional outcomes will be assessed in a composite primary outcome, with success defined as circumferential resection margin ≥1 mm, TME grade III, and minimal postoperative morbidity (absence of Clavien-Dindo grade III-IV complications within 30 days after surgery). Secondary endpoints will include the co-primary endpoints over the long-term (2 years), quality of surgery, quality of life, length of hospital stay, operative time, and rate of unplanned conversions.

Enrollment

1,098 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Age ≥ 18 years old

  2. Rectal adenocarcinoma from middle and lower third (less than 10 cm from the anal verge) with a sphincter saving procedure

  3. High risk operative patients (two of these factors as assessed on MRI):

    1. Obese patient with a BMI > 30 (male or female)
    2. Narrow pelvis: inter-tuberous distance < 10 cm
    3. Large tumoral volume with suspicion of close predictive margin (CRM ≤ 1 mm) at diagnosis
    4. Expected coloanal or ultra-low colorectal anastomosis
  4. Patients with adequate performance status (Eastern Cooperative Oncology Group Scale score of ≤2)

  5. Patient has signed and dated the informed consent before inclusion in the study.

Exclusion criteria

  1. Patient with a comorbid illness or condition that would preclude the use of surgery.
  2. Patients with T4b tumors which impose a pelvectomy
  3. Patient requires an abdominal perineal resection (APR)
  4. Patients with concurrent or previous invasive pelvic malignant tumors (cervical, uterine, or rectal; excluding the prostate) within 5 years before study enrollment
  5. Patient undergoing emergency procedures
  6. Planned rectal surgery along with major concomitant procedures (e.g. hepatectomies, other intestinal resections)
  7. Metastatic disease
  8. Pregnant or suspected pregnancy
  9. Patients unwilling to comply with all follow-up study requirements
  10. Patient included in another study which impact on the surgical technique or its choice.

Trial design

1,098 participants in 4 patient groups

Open laparotomy
Description:
A surgical procedure involving a large incision through the abdominal wall to gain access into the abdominal cavity.
Treatment:
Procedure: TME with LAR
Laparoscopic surgery
Description:
A minimally-invasive technique in which operations are performed via small incisions (usually 0.5-1.5 cm) at a location distant to the site of interest.
Treatment:
Procedure: TME with LAR
Robot-assisted surgery using the da Vinci® Surgical System
Description:
A minimally-invasive approach that allows good precision, flexibility, and control.
Treatment:
Procedure: TME with LAR
Transanal surgery through the anus
Description:
Where the protectomy is performed down to up until the Douglas pouch
Treatment:
Procedure: TME with LAR

Trial contacts and locations

1

Loading...

Central trial contact

Jean-Pierre Bleuse, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems